SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 2.40 |
| Enterprise Value ($M) | -0.46 |
| Book Value ($M) | 13.88 |
| Book Value / Share | 2.31 |
| Price / Book | 0.17 |
| NCAV ($M) | 10.49 |
| NCAV / Share | 1.75 |
| Price / NCAV | 0.23 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.50 |
| Return on Assets (ROA) | -0.47 |
| Return on Equity (ROE) | -0.58 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 4.81 |
| Current Ratio | 4.81 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 13.24 |
| Assets | 16.63 |
| Liabilities | 2.75 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | -7.49 |
| Net Income | -6.91 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -6.14 |
| Cash from Investing | 0.80 |
| Cash from Financing | 6.18 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Biotechnology Value Fund L P | 0.00 | -100.00 | |
| 13G/A | CVI Investments, Inc. | 9.90 | 99.85 | |
| 13G/A | Baharaff Allen | 6.20 | -93.04 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 8,307 | 50,418 | 16.48 | |
| 25,584 | 64,908 | 39.42 | |
| 34,625 | 12,628 | 274.19 | |
| 5,027 | 856 | 587.27 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| GALT – Galectin Therapeutics Inc. | GDTC – CytoMed Therapeutics Limited |
| GHSI – Guardion Health Sciences, Inc. | GLSI – Greenwich LifeSciences, Inc. |
| GLTO – Galecto, Inc. |
Financial data and stock pages provided by
Fintel.io